FastTest. You ve read the book now test yourself

Size: px
Start display at page:

Download "FastTest. You ve read the book... ... now test yourself"

Transcription

1 FastTest You ve read the book now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. Please refer back to relevant sections of the book to address any areas of uncertainty. Which of the following statements are correct? Note: there may be more than one correct answer per question.

2 1 Epidemiology and pathophysiology 1. In terms of the incidence of psoriasis: a) chronic plaque psoriasis is the most common form of the disease b) there is considerable interracial variation c) the peak age of onset is years d) men are more commonly affected than women 2. There are two types of chronic plaque psoriasis type I (common) and type II (uncommon). a) Type 1 tends to occur in young adults b) A positive family history is uncommon in patients with type I disease c) Type I disease tends to be mild and localized d) Type I disease tends to run an irregular course

3 3. The pathogenesis of psoriasis involves the interplay between environmental and genetic factors. a) Over 50% of patients with psoriasis have a known family history of the disease b) Nutritional deficiencies can be an important environmental trigger c) Excessive alcohol intake is associated with disease deterioration d) The major psoriasis genetic locus, PSORS1, contributes up to 50% of the genetic risk

4 2 Clinical presentation 4. Important clues to the diagnosis of psoriasis include a history of: a) atopic asthma and/or eczema b) persistent dandruff and/or scaling in the ears c) skin allergies d) joint problems e) autoimmune disease 5. Typically, chronic plaque psoriasis is: a) discoid in shape b) not itchy c) symmetrically distributed d) more common on thinner areas of skin

5 6. Comorbidities associated with psoriasis include: a) Crohn s disease b) lymphoma c) eczema d) metabolic syndrome e) cardiovascular disease

6 3 Differential diagnoses 7. A number of dermatological conditions may be confused with psoriasis. a) Mycological specimens should be taken from skin, hair or nails to differentiate Tinea infection (ringworm) from psoriasis b) The Koebner phenomenon is found in lichen planus but not in psoriasis c) A skin biopsy should be taken to differentiate psoriasis from hyperkeratotic forms of eczema on the hands and feet d) Contact dermatitis is seldom symmetrical and is more pruritic than psoriasis

7 8. Which of the following is/are psoriasis? (a) (b) (c) (d) (e) (f)

8 4 General management approach 9. Before starting treatment, useful advice for patients includes: a) Reassurance that early treatment can prevent the disease from becoming more severe b) Details of local side effects such as irritation or staining c) The benefits of active treatment, even for mild disease d) Information about stress reduction and management e) A warning that treatment is likely to be lengthy

9 10. Psoriasis is a chronic disease that requires long-term therapy. a) Relapse is likely if therapy is discontinued b) Longer-term remissions can be achieved with combined or rotational therapies than with any individual modality c) Combination therapy increases drug-related toxicity d) More toxic agents can be used to clear psoriasis followed by less toxic agents to maintain remission

10 5 Topical therapy 11. Choice of formulation will depend on patient preference and the site/pattern of psoriasis. a) Lotions tend to be most suitable for use at flexural sites b) Creams are less greasy than ointments and are therefore often prescribed for the face c) Ointments tend to be the preferred formulation for plaque psoriasis on the body d) Topical agents are particularly useful for the treatment of nail psoriasis

11 12. Corticosteroids are an integral component of topical therapy (first-line therapy in the UK and USA for chronic plaque psoriasis). a) Continuous use of corticosteroids may lead to loss of efficacy b) On stopping corticosteroid therapy, rebound psoriasis and a more inflammatory form of the disease may develop c) Side effects include irreversible skin bleaching d) Moderate or severe atopic eczema may complicate the use of topical corticosteroids e) Corticosteroids should be used alternately or in rotation with non-steroid-based therapies

12 13. The vitamin D 3 analogs calcipotriol, tacalcitol and calcitriol are all effective in chronic plaque psoriasis (first-line therapy in the UK and Europe). a) Efficacy is comparable to that of topical corticosteroids with mid-to-high potency b) Local side effects include tachyphylaxis and skin staining c) Onset of action is quicker than that of topical corticosteroids d) These agents can be used in combination with corticosteroids, phototherapy or systemic agents

13 6 Phototherapy and photochemotherapy 14. Phototherapy involves whole-body exposure to artificial sources of ultraviolet (UV) radiation a) Phototherapy involves the application of UVA radiation to the epidermis b) Phototherapy is usually given once weekly c) Topical corticosteroids used concurrently with phototherapy may increase relapse rates d) Phototherapy is well tolerated during pregnancy

14 15. Photochemotherapy (PUVA) involves the application of a photosensitizing drug (methoxsalen) in combination with UVA radiation. a) PUVA is contraindicated in patients with localized recalcitrant disease (e.g. palmar plantar psoriasis) b) Remission rates with PUVA are inferior to most other forms of therapy c) Methoxsalen remains in the eye for up to 12 hours after ingestion, necessitating appropriate eye protection after treatment d) PUVA is associated with a significant long-term risk of skin cancer

15 7 Systemic therapy 16. With systemic therapy, the benefits of disease clearance must be balanced against the risk of short- and long-term side effects. a) Most systemic therapies are associated with immunosuppression b) Systemic retinoids should be not be used in combination with PUVA c) Women should be advised to avoid conception for up to a year after acitretin therapy d) With ciclosporin therapy, the more inflammatory the psoriasis the more dramatic the response 17. Methotrexate is the gold standard of systemic therapy. a) Folic acid supplementation should be given concurrently with methotrexate b) Abrupt discontinuation of methotrexate may destabilize the psoriasis, which can lead to inflammatory flares c) Methotrexate is contraindicated during pregnancy or breastfeeding d) Methotrexate can be administered orally, intramuscularly or subcutaneously

16 8 Receptor-targeted (biological) therapies 18. Biological therapy targets specific molecules involved in the immunopathogenesis of psoriasis. a) At present, biological therapy is only licensed for patients with psoriatic joint disease b) Currently available biological agents are all administered by injection c) The biological agents used to treat psoriasis are associated with significant hepatotoxicity that warrants careful monitoring d) Biological therapies potentially reduce cardiovascular events in the psoriasis population

17 9 Psoriatic arthritis 19. Psoriatic arthritis is a common autoimmune inflammatory condition affecting the joints and entheses of patients with psoriasis. a) Onset of the disease is most common in people in their 20s and 30s b) Psoriatic arthritis, when it occurs, usually emerges before the appearance of skin lesions, which makes diagnosis difficult c) Women are more commonly affected than men d) Blood testing for rheumatoid factor is usually positive

18 20. In the treatment of psoriatic arthritis: a) long-term therapy with COX-2 inhibitors is a feasible option in patients with mild disease b) both methotrexate and ciclosporin have been shown to yield clinically significant improvements in joint disease c) biological therapies have been shown to inhibit the progression of structural damage d) biological therapies have been shown to significantly reduce fatigue, and improve function and quality of life

19 Thank you for taking this FastTest. There is no final score or certificate, but by reinforcing your understanding you have enhanced your clinical skills and practice. If you found the book useful, please spread the word about Fast Facts to your colleagues, students and patients.

X-Plain Psoriasis Reference Summary

X-Plain Psoriasis Reference Summary X-Plain Psoriasis Reference Summary Introduction Psoriasis is a long-lasting skin disease that causes the skin to become inflamed. Patches of thick, red skin are covered with silvery scales. It affects

More information

Psoriasis Treatment Transition Pathway

Psoriasis Treatment Transition Pathway Psoriasis Treatment Transition Pathway A Treatment Support Tool Adapted from Circle Nottingham NHS Treatment Centre Psoriasis Pathway (under consultation) with support from Abbvie Ltd Treatment Pathways

More information

Psoriasis. Psoriasis. Mark A. Bechtel, M.D. Director of Dermatology The Ohio State University College of Medicine

Psoriasis. Psoriasis. Mark A. Bechtel, M.D. Director of Dermatology The Ohio State University College of Medicine Psoriasis Mark A. Bechtel, M.D. Director of Dermatology The Ohio State University College of Medicine Psoriasis Psoriasis is a chronic skin disorder resulting from a polygenic predisposition combined with

More information

How To Take Methotrexate By Injection

How To Take Methotrexate By Injection How To Take Methotrexate By Injection 1 how long does it take for methotrexate to work for abortion 2 methotrexate 15 mg hair loss 3 methotrexate injection dosage for rheumatoid arthritis 4 order methotrexate

More information

PATIENT RESOURCES: PSORIASIS

PATIENT RESOURCES: PSORIASIS PATIENT RESOURCES: PSORIASIS Psoriasis is a persistent skin disorder in which there are red, thickened areas with silvery scales, most often on the scalp, elbows, knees, and lower back. Some cases, of

More information

Psoriasis. Student's Name. Institution. Date of Submission

Psoriasis. Student's Name. Institution. Date of Submission Running head: PSORIASIS Psoriasis Student's Name Institution Date of Submission PSORIASIS 1 Abstract Psoriasis is a non-contagious chronic skin disease that is characterized by inflammatory and multiplying

More information

Is Monotherapy Treatment of Etanercept Effective Against Plaque Psoriasis?

Is Monotherapy Treatment of Etanercept Effective Against Plaque Psoriasis? Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2011 Is Monotherapy Treatment of Etanercept

More information

Cutaneous Lymphoma FAST FACTS

Cutaneous Lymphoma FAST FACTS Cutaneous Lymphoma FAST FACTS What is Cutaneous Lymphoma? Cutaneous lymphomas are types of non-hodgkin s lymphomas (NHL) that originate in the lymphocytes (white blood cells). Unlike most other types of

More information

2-5 % Europeans A distressing, life-long, inflammatory disease Impairs patients Quality of Life

2-5 % Europeans A distressing, life-long, inflammatory disease Impairs patients Quality of Life Psoriasis: 2-5 % Europeans A distressing, life-long, inflammatory disease Impairs patients Quality of Life 15-25%: moderate-to-severe disease - candidates for systemic therapies - often difficult to manage

More information

Treatment options a simple guide

Treatment options a simple guide Guide Treatment options a simple guide To decide which treatment is right for you, a good starting point is to know what options you have and to understand the pros and cons of each one. People respond

More information

How To Choose A Biologic Drug

How To Choose A Biologic Drug North Carolina Rheumatology Association Position Statements I. Biologic Agents A. Appropriate delivery, handling, storage and administration of biologic agents B. Indications for biologic agents II. III.

More information

PSORIASIS AND ITS. Learn how vitamin D medications play an important role in managing plaque psoriasis

PSORIASIS AND ITS. Learn how vitamin D medications play an important role in managing plaque psoriasis PLAQUE PSORIASIS AND ITS TREATMENTS Learn how vitamin D medications play an important role in managing plaque psoriasis 2 Understanding Plaque Psoriasis WHAT CAUSES PLAQUE PSORIASIS? No one knows exactly

More information

Public Forum on Psoriasis. 2011 National Series

Public Forum on Psoriasis. 2011 National Series Public Forum on Psoriasis 2011 National Series Jerry Tan MD FRCPC Schulich School of Medicine and Dentistry, University of Western Ontario Windsor, Ontario, Canada Presented at Caboto Club, Windsor, April

More information

FastTest. You ve read the book... ... now test yourself

FastTest. You ve read the book... ... now test yourself FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to

More information

Topical Tacrolimus or Pimecrolimus for the treatment of mild, moderate or severe atopic eczema. Effective Shared Care Agreement

Topical Tacrolimus or Pimecrolimus for the treatment of mild, moderate or severe atopic eczema. Effective Shared Care Agreement Topical Tacrolimus or Pimecrolimus for the treatment of mild, moderate or severe atopic eczema. Effective Shared Care Agreement A Copy of this page signed by all three parties should be retained in the

More information

Summary of the risk management plan (RMP) for Otezla (apremilast)

Summary of the risk management plan (RMP) for Otezla (apremilast) EMA/741412/2014 Summary of the risk management plan (RMP) for Otezla (apremilast) This is a summary of the risk management plan (RMP) for Otezla, which details the measures to be taken in order to ensure

More information

Methotrexate Dose For Juvenile Rheumatoid Arthritis

Methotrexate Dose For Juvenile Rheumatoid Arthritis Methotrexate Dose For Juvenile Rheumatoid Arthritis should i take methotrexate for my ra methotrexate 50 mg/ml methotrexate sodium 2.5mg tablets what is the usual dosage of methotrexate for ra methotrexate

More information

www.healthoracle.org 1

www.healthoracle.org 1 How does hair grow and should it recycle? A single hair follicle grows its hair strand over a period of four to six years (the anagen phase). It then rests for two to four months (the telogen phase), after

More information

Evidence-based Management of Rheumatoid Arthritis (2009)

Evidence-based Management of Rheumatoid Arthritis (2009) CPLD reviews its distance learning programmes every twelve months to ensure currency. This update has been produced by an expert and should be read in conjunction with the Evidencebased Management of distance

More information

National Medicines Information Centre ST. JAMES S HOSPITAL DUBLIN 8 TEL 01-4730589 or 1850-727-727 FAX 01-4730596 E-Mail: nmic@stjames.

National Medicines Information Centre ST. JAMES S HOSPITAL DUBLIN 8 TEL 01-4730589 or 1850-727-727 FAX 01-4730596 E-Mail: nmic@stjames. VOLUME 6 NUMBER 6 2000 PSORIASIS National Medicines Information Centre ST. JAMES S HOSPITAL DUBLIN 8 TEL 01-4730589 or 1850-727-727 FAX 01-4730596 E-Mail: nmic@stjames.ie SUMMARY The aim of treatment is

More information

TREATMENTS FOR MODERATE OR SEVERE PSORIASIS

TREATMENTS FOR MODERATE OR SEVERE PSORIASIS TREATMENTS FOR MODERATE OR SEVERE PSORIASIS What are the aims of this leaflet? Patients with psoriasis are usually treated with creams and ointments, which are applied to the skin. These are discussed

More information

Efficacy and Safety of Calcipotriol Ointment in Psoriasis Vulgaris - Experiences in Hong Kong

Efficacy and Safety of Calcipotriol Ointment in Psoriasis Vulgaris - Experiences in Hong Kong ORIGINAL ARTICLES Efficacy and Safety of Calcipotriol Ointment in Psoriasis Vulgaris - Experiences in Hong Kong Drs. C. W. Fung, L.Y. Chong, C.Y. Leung, C. N. Look, K.K. Lo, K. M. Ho Social Hygiene Service

More information

TOPICAL TREATMENTS FOR PSORIASIS

TOPICAL TREATMENTS FOR PSORIASIS TOPICAL TREATMENTS FOR PSORIASIS What are the aims of this leaflet? Patients with psoriasis are usually treated with preparations that are applied to the skin. This leaflet has been written to help you

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure

More information

biologics for the treatment of psoriasis

biologics for the treatment of psoriasis How to contact us The Psoriasis Association Dick Coles House 2 Queensbridge Northampton NN4 7BF tel: 08456 760 076 (01604) 251 620 fax: (01604) 251 621 email: mail@psoriasis-association.org.uk www.psoriasis-association.org.uk

More information

Methotrexate (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023

Methotrexate (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023 Brochure More information from http://www.researchandmarkets.com/reports/3128342/ Methotrexate (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023 Description: Methotrexate (Rheumatoid Arthritis)

More information

Prescribing advice for the management and treatment of psoriasis

Prescribing advice for the management and treatment of psoriasis Prescribing advice for the management and treatment of psoriasis This guidance contains suggested advice for the management and treatment of patients presenting with psoriasis. This guidance applies to

More information

PSORIASIS. -Multi factorial. -Papulosquamous disorder. -Genetically determined (few) -Chronic Scaly lesions. -Seasonal variations

PSORIASIS. -Multi factorial. -Papulosquamous disorder. -Genetically determined (few) -Chronic Scaly lesions. -Seasonal variations PSORIASIS -Multi factorial -Papulosquamous disorder -Genetically determined (few) -Chronic Scaly lesions -Seasonal variations -Recurrences & remissions Etiology & Pathogenesis T-cell mediated autoimmune

More information

Biologic Treatments for Rheumatoid Arthritis

Biologic Treatments for Rheumatoid Arthritis Biologic Treatments Rheumatoid Arthritis (also known as cytokine inhibitors, TNF inhibitors, IL 1 inhibitor, or Biologic Response Modifiers) Description Biologics are new class of drugs that have been

More information

Your psoriasis story. Print this out, answer the questions, then share it with your doctor

Your psoriasis story. Print this out, answer the questions, then share it with your doctor Your psoriasis story Print this out, answer the questions, then share it with your doctor 1 SYMPTOMS Surface Area Your doctor will use a variety of different factors to measure the severity of your disease,

More information

Treating Psoriasis Naturally. Dr. Deborah Ardolf, ND

Treating Psoriasis Naturally. Dr. Deborah Ardolf, ND Treating Psoriasis Naturally by Dr. Deborah Ardolf, ND Psoriasis is an extremely common, noncontagious skin disorder affecting between 2% to 4% of the United States population. Psoriasis affects men and

More information

Department of Dermatology, Churchill Hospital PUVA Treatment

Department of Dermatology, Churchill Hospital PUVA Treatment Oxford University Hospitals NHS Trust Department of Dermatology, Churchill Hospital PUVA Treatment information for patients CONTENTS What is PUVA 3 What conditions are treated with PUVA? 3 How is PUVA

More information

Current Rheumatoid Arthritis Treatment Options: Update for Managed Care and Specialty Pharmacists

Current Rheumatoid Arthritis Treatment Options: Update for Managed Care and Specialty Pharmacists Current Rheumatoid Arthritis Treatment Options: Update for Managed Care and Specialty Pharmacists 1. Which of the following matches of biologic targets that contribute to rheumatoid arthritis (RA) and

More information

Phenotypes and Classification of Psoriasis

Phenotypes and Classification of Psoriasis Rheumatology 2010 Birmingham 21 April 2010 Phenotypes and Classification of Psoriasis Christopher E.M. Griffiths Abbott Centocor Incyte Galderma Janssen-Cilag Leo Pharma Lynxx Novartis Pfizer Schering-Plough

More information

Common Skin Conditions in Children. Liz Moore and Emma King Dermatology Nurse Consultants

Common Skin Conditions in Children. Liz Moore and Emma King Dermatology Nurse Consultants Common Skin Conditions in Children Liz Moore and Emma King Dermatology Nurse Consultants Diagnosis? Nummular Dermatitis Disc pattern rash (discoid eczema) Clearly demarcated edges Occurs at any age Can

More information

Psoriasis: Controlled YOUR GUIDE TO BIOLOGICAL TREATMENTS FOR PLAQUE PSORIASIS

Psoriasis: Controlled YOUR GUIDE TO BIOLOGICAL TREATMENTS FOR PLAQUE PSORIASIS Psoriasis: Controlled YOUR GUIDE TO BIOLOGICAL TREATMENTS FOR PLAQUE PSORIASIS 2 Proudly supported by Disclaimer: Some photographs and models used in this booklet are for illustrative purposes only and

More information

GP Symposium Dermatology Dr Seow Hoong Foo Dr Shireen Velangi March 6th 2014

GP Symposium Dermatology Dr Seow Hoong Foo Dr Shireen Velangi March 6th 2014 Psoriasis : It s not just skin de eep NICE Guidelines and Quality Standards: a collaboration to deliver quality care GP Symposium Dermatology y p gy Dr Seow Hoong Foo Dr Shireen Velangi March 6th 2014

More information

Psoriatic Arthritis www.arthritis.org.nz

Psoriatic Arthritis www.arthritis.org.nz Psoriatic Arthritis www.arthritis.org.nz Did you know? Arthritis affects one in six New Zealanders over the age of 15 years. Psoriatic arthritis usually appears in people between the ages of 30 to 50.

More information

Psoriasis - suspected

Psoriasis - suspected Psoriasis - suspected Possible link to alcohol use, depression, other medications History and examination Consider referral to Health Trainers Consider differential diagnoses Is the patient systemically

More information

Psoriasis is a skin condition that causes scaly red patches on your skin. There's no cure for psoriasis, but there are treatments that can help.

Psoriasis is a skin condition that causes scaly red patches on your skin. There's no cure for psoriasis, but there are treatments that can help. Patient information from the BMJ Group Psoriasis What is it? What are the symptoms? How is it diagnosed? How common is it? What treatments work? What will happen? Questions to ask Psoriasis If you get

More information

Treating psoriasis and psoriatic arthritis. A booklet for patients and carers

Treating psoriasis and psoriatic arthritis. A booklet for patients and carers Treating psoriasis and psoriatic arthritis A booklet for patients and carers Picture credits Cover Stuart Neville Page 4 Dr P. Marazzi/Science Photo Library CNRI/Science Photo Library CID, ISM/Science

More information

Professor Andrew Wright,

Professor Andrew Wright, Professor Andrew Wright, Systemic treatments are drugs taken as tablets or injections that travel through the bloodstream, dampening down the immune system to reach and treat eczema all over the body.

More information

subcutaneous initially every 4 weeks then every 12 weeks Coverage Criteria: Express Scripts, Inc. monograph dated 02/24/2010

subcutaneous initially every 4 weeks then every 12 weeks Coverage Criteria: Express Scripts, Inc. monograph dated 02/24/2010 BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Humira (adalimumab subcutaneous injection) Commercial HMO/PPO/CDHP

More information

Preetha selva et al. / International Journal of Phytopharmacology. 6(1), 2015, 42-46. International Journal of Phytopharmacology

Preetha selva et al. / International Journal of Phytopharmacology. 6(1), 2015, 42-46. International Journal of Phytopharmacology International Journal of Phytopharmacology Journal homepage: www.onlineijp.com 42 e- ISSN 0975 9328 Print ISSN 2229 7472 IJP A CLINICAL STUDY TO EVALUATE THE EFFECT OF TOPICAL TAZAROTENE IN THE TREATMENT

More information

CLINICAL BRIEFS. Considerations for the Clinical Assessment of the Patient With Plaque Psoriasis. By Amy Krajacic

CLINICAL BRIEFS. Considerations for the Clinical Assessment of the Patient With Plaque Psoriasis. By Amy Krajacic CLINICAL BRIEFS Considerations for the Clinical Assessment of the Patient With Plaque Psoriasis By Amy Krajacic Senior Medical Editor, Custom Publications MediMedia USA, Yardley, Pa. A review of recently

More information

Top 10 Psoriasis Treatment Tips

Top 10 Psoriasis Treatment Tips Top 10 Psoriasis Treatment Tips Steven R. Feldman, MD, PhD Professor of Dermatology, Pathology & Social Sciences Director, Psoriasis Treatment Center Wake Forest University School of Medicine Winston-Salem,

More information

completenutrition I R E L A N D The Role of Fulvic Acid in Skin Health By Peter Gouge BSc (Hons) Nutrition, RNutr

completenutrition I R E L A N D The Role of Fulvic Acid in Skin Health By Peter Gouge BSc (Hons) Nutrition, RNutr The Role of Fulvic Acid in Skin Health By Peter Gouge BSc (Hons) Nutrition, RNutr Copyright 2009 The skin is the largest organ in the Human body and along with this it is our indicator of poor health.

More information

For more information, please contact the National Psoriasis Foundation at 800-723-9166 or

For more information, please contact the National Psoriasis Foundation at 800-723-9166 or For more information, please contact the National Psoriasis Foundation at 800-723-9166 or www.psoriasis.org. PSORIASIS 101: LEARNING TO LIVE IN THE SKIN YOU RE IN is part of an awareness program to educate

More information

MEDICATION GUIDE STELARA

MEDICATION GUIDE STELARA MEDICATION GUIDE STELARA (stel ar a) (ustekinumab) Injection What is the most important information I should know about STELARA? STELARA is a medicine that affects your immune system. STELARA can increase

More information

VITILIGO Charles Camisa, MD 1/24/12. Vitiligo is a common autoimmune skin disease that causes gradual loss of the natural

VITILIGO Charles Camisa, MD 1/24/12. Vitiligo is a common autoimmune skin disease that causes gradual loss of the natural VITILIGO Charles Camisa, MD 1/24/12 What is vitiligo? Vitiligo is a common autoimmune skin disease that causes gradual loss of the natural brown pigment in the skin called melanin. It affects about 1%

More information

Results of the first clinical study on a new treatment for Psori asis: the T.M.S.T. method

Results of the first clinical study on a new treatment for Psori asis: the T.M.S.T. method MINERAL MOR LTD Results of the first clinical study on a new treatment for Psori asis: the TMST method Marco Harari MD 12122012 Conclusions: 1 No side effects were recorded during the 5week study period

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Multiple Technology Appraisal

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Multiple Technology Appraisal NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Multiple Technology Appraisal Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional

More information

CAN-FITE BIOPHARMA LTD.

CAN-FITE BIOPHARMA LTD. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month

More information

Guidelines of care for the management of psoriasis and psoriatic arthritis

Guidelines of care for the management of psoriasis and psoriatic arthritis FROM THE ACADEMY Guidelines of care for the management of psoriasis and psoriatic arthritis Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations

More information

Once the immune system is triggered, cells migrate from the blood into the joints and produce substances that cause inflammation.

Once the immune system is triggered, cells migrate from the blood into the joints and produce substances that cause inflammation. HealthExchange Points For Your Joints An Arthritis Talk Howard Epstein, MD Orthopaedic & Rheumatologic Institute Rheumatic & Immunologic Disease Cleveland Clinic Beachwood Family Health & Surgery Center

More information

Guideline for the use of Biological Therapies in the Treatment of Psoriasis

Guideline for the use of Biological Therapies in the Treatment of Psoriasis 1 Date of Production: March1 st 2011 Date of 1 st review: July 10 th 2015 Date for next review: March1 st 2018 Local Contact Dermatology Consultant Shanti Ayob Patient group to which this applies: Patients

More information

Immune Modulating Drugs Prior Authorization Request Form

Immune Modulating Drugs Prior Authorization Request Form Patient: HPHC member ID #: Requesting provider: Phone: Servicing provider: Diagnosis: Contact for questions (name and phone #): Projected start and end date for requested Requesting provider NPI: Fax:

More information

Guidelines of care for the management of psoriasis and psoriatic arthritis

Guidelines of care for the management of psoriasis and psoriatic arthritis FROM THE ACADEMY Guidelines of care for the management of psoriasis and psoriatic arthritis Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations

More information

Psoriatic Arthritis. Psoriatic Arthritis 3/05

Psoriatic Arthritis. Psoriatic Arthritis 3/05 Psoriatic Arthritis 3/05 Psoriatic Arthritis Arthritis Ireland, 1 Clanwilliam Square, Grand Canal Quay, Dublin 2 T: (01) 661 8188 F: (01) 661 8261 www.arthritisireland.ie What is in this booklet? This

More information

Rheumatoid Arthritis monitoring of DMARDs

Rheumatoid Arthritis monitoring of DMARDs www.bpac.org.nz keyword: DMARDS Rheumatoid Arthritis monitoring of DMARDs Key reviewers: Professor John Highton, Head of Section, Department of Medical and Surgical Sciences, Dunedin School of Medicine,

More information

Original Policy Date

Original Policy Date MP 5.01.20 Tysabri (natalizumab) Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Local Policy/12:2013 Return to Medical Policy Index Disclaimer

More information

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES `I. Requirements for Prior Authorization of Cytokine and CAM Antagonists

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES `I. Requirements for Prior Authorization of Cytokine and CAM Antagonists MEDICAL ASSISTANCE HBOOK `I. Requirements for Prior Authorization of Cytokine and CAM Antagonists A. Prescriptions That Require Prior Authorization All prescriptions for Cytokine and CAM Antagonists must

More information

Psoriatic arthritis FACTSHEET

Psoriatic arthritis FACTSHEET 1 What is psoriatic arthritis? Psoriatic arthritis (PsA) is a disease where joints around the body become inflamed and sore. It can make moving about difficult and painful. People who have PsA also have

More information

Welcome to the December 2011 newsletter from Pure Bio Ltd.

Welcome to the December 2011 newsletter from Pure Bio Ltd. Your Monthly Update Dear Colleague Welcome to the December 2011 newsletter from Pure Bio Ltd. Did you know: Latest research from Tufts Medical Centre, Boston MA has shown that high dietary intake of vitamin

More information

Efficacy and safety of simvastatin in chronic plaque psoriasis

Efficacy and safety of simvastatin in chronic plaque psoriasis Original Article Efficacy and safety of simvastatin in chronic plaque psoriasis Shazia Aslam, Khawar Khurshid, Faria Asad, Zahida Rani,Sabrina Suhail Pal Department of Dermatology, Unit II, King Edward

More information

Autoimmune Diseases More common than you think Randall Stevens, MD

Autoimmune Diseases More common than you think Randall Stevens, MD Autoimmune Diseases More common than you think Randall Stevens, MD picture placeholder Autoimmune Diseases More than 60 different disorders Autoimmune disorders (AID) diseases caused by the immune system

More information

INITIATING ORAL AUBAGIO (teriflunomide) THERAPY

INITIATING ORAL AUBAGIO (teriflunomide) THERAPY FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY WARNING: HEPATOTOXICITY AND RISK OF TERATOGENICITY Severe liver injury including fatal liver failure has been

More information

Rheumatoid Arthritis

Rheumatoid Arthritis What is Rheumatoid Arthritis? Rheumatoid Arthritis (RA) is a chronic and systemic disease that causes pain, stiffness, swelling, and limitation in the motion and function of multiple joints. Though joints

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. VITAMINE B12 STEROP 1mg/1ml Solution for injection / oral solution. Cyanocobalamin

PACKAGE LEAFLET: INFORMATION FOR THE USER. VITAMINE B12 STEROP 1mg/1ml Solution for injection / oral solution. Cyanocobalamin PACKAGE LEAFLET: INFORMATION FOR THE USER VITAMINE B12 STEROP 1mg/1ml Solution for injection / oral solution Cyanocobalamin Read all of this leaflet carefully before you start using this medicine because

More information

Psoriasis and Psoriatic Arthritis Alliance

Psoriasis and Psoriatic Arthritis Alliance Psoriasis and Psoriatic Arthritis Alliance A principal source of information on psoriasis and psoriatic arthritis ) Treatments for Psoriatic Arthritis overview Although psoriatic arthritis is a chronic

More information

Drug Therapy Guidelines: Humira (adalimumab)

Drug Therapy Guidelines: Humira (adalimumab) Drug Therapy Guidelines: Humira (adalimumab) Effective Date: 5/1/08 Committee Review Date: 1/6/01, 9/18/01, 1/15/02, 1/7/03, 1/20/04, 1/18/05, 12/7/05, 10/15/06, 7/2/07, 11/5/07, 3/25/08 Policy Statements:

More information

Guidelines of care for the management of psoriasis and psoriatic arthritis

Guidelines of care for the management of psoriasis and psoriatic arthritis FROM THE ACADEMY Guidelines of care for the management of psoriasis and psoriatic arthritis Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies Alan Menter,

More information

MEDICATION GUIDE. PROTOPIC [pro-top-ik] (tacrolimus) Ointment 0.03% Ointment 0.1%

MEDICATION GUIDE. PROTOPIC [pro-top-ik] (tacrolimus) Ointment 0.03% Ointment 0.1% MEDICATION GUIDE PROTOPIC [pro-top-ik] (tacrolimus) Ointment 0.03% Ointment 0.1% Read the Medication Guide every time you or a family member gets PROTOPIC Ointment. There may be new information. This Medication

More information

1g cream or ointment contains 1 mg methylprednisolone aceponate.

1g cream or ointment contains 1 mg methylprednisolone aceponate. CONSUMER MEDICINE INFORMATION ADVANTAN 1g cream or ointment contains 1 mg methylprednisolone aceponate. What is in this leaflet Please read this leaflet carefully before you start using ADVANTAN. It will

More information

Core therapeutic areas

Core therapeutic areas Core therapeutic areas Platforms for growth Luke Miels, Executive Vice President, Global Portfolio & Product Strategy and Corporate Affairs Current business is led by core therapeutic areas Sales 9M 2014

More information

Treating your skin condition with narrowband ultraviolet B radiation (NB-UVB)

Treating your skin condition with narrowband ultraviolet B radiation (NB-UVB) Treating your skin condition with narrowband ultraviolet B radiation (NB-UVB) Your doctor has referred you to the Dowling Day Treatment Centre for a course of narrow band ultraviolet treatment for your

More information

How To Treat Psoriasis With Omega 3 Fatty Acids

How To Treat Psoriasis With Omega 3 Fatty Acids CAN PSORIASIS TREATMENT BE AIDED BY OMEGA-3 FATTY ACIDS? Brittney Urban Psoriasis Chronic skin disease Cell life cycle build up Can be disabling Symptoms: Red patches with silvery scales Dry, cracked skin

More information

Nail Psoriasis. A positive approach. to psoriasis and. psoriatic arthritis

Nail Psoriasis. A positive approach. to psoriasis and. psoriatic arthritis Nail Psoriasis A positive approach to psoriasis and psoriatic arthritis What is psoriasis? Psoriasis (Ps) is a long-term (chronic) scaling disease of the skin, which affects 2% 3% of the UK population.

More information

First Name. Profession. Weight lbs. Weight 1 year ago lbs. Min. Adult Weight lbs. at age Maximum Weight lbs. at age

First Name. Profession. Weight lbs. Weight 1 year ago lbs. Min. Adult Weight lbs. at age Maximum Weight lbs. at age Date Time Dietary consultation involves a health profile whose purpose is not to establish a diagnosis, but rather to determine a client's health status in order to guide his or her weight loss plan. A

More information

CICLOSPORIN. What are the aims of this leaflet?

CICLOSPORIN. What are the aims of this leaflet? CICLOSPORIN What are the aims of this leaflet? This leaflet has been written to help you understand more about ciclosporin. It tells you what it is, how it works, how it is used to treat skin conditions,

More information

LEFLUNOMIDE (Adults)

LEFLUNOMIDE (Adults) Shared Care Guideline DRUG: Introduction: LEFLUNOMIDE (Adults) Indication: Disease modifying drug for rheumatoid arthritis and psoriatic arthritis Licensing Information: Disease modifying drug for active

More information

Rheumatoid Arthritis

Rheumatoid Arthritis Rheumatoid Arthritis While rheumatoid arthritis (RA) has long been feared as one of the most disabling types of arthritis, the outlook has dramatically improved for many newly diagnosed patients. Certainly

More information

Markham Stouffville Hospital

Markham Stouffville Hospital Markham Stouffville Hospital Adult Diabetes Education Frequently Asked Questions What is diabetes? Diabetes is a disease in which blood glucose levels are above normal. Most of the food we eat is turned

More information

Guideline on the management of psoriasis in South Africa

Guideline on the management of psoriasis in South Africa Guideline on the management of psoriasis in South Africa N Raboobee (Chair of Working Group), J Aboobaker, H F Jordaan, W Sinclair, J M Smith, G Todd, R Weiss, D Whitaker, Working Group of the Dermatological

More information

Case Scenarios. Case Scenario 1 Group A

Case Scenarios. Case Scenario 1 Group A Case Scenarios Prior to the workshop please work through the following scenario and be prepared to present this to the rest of the group. You can work in groups of 3-4. Specialist nurses, phototherapy

More information

Winter 2013. Changing landscapes, pipeline products and plan sponsor impact

Winter 2013. Changing landscapes, pipeline products and plan sponsor impact Winter 2013 Changing landscapes, pipeline products and plan sponsor impact Changing landscapes, pipeline products and plan sponsor impact The pharmaceutical landscape is changing as is the profile of blockbuster

More information

Sponsor Novartis. Generic Drug Name Secukinumab. Therapeutic Area of Trial Psoriasis. Approved Indication investigational

Sponsor Novartis. Generic Drug Name Secukinumab. Therapeutic Area of Trial Psoriasis. Approved Indication investigational Clinical Trial Results Database Page 2 Sponsor Novartis Generic Drug Name Secukinumab Therapeutic Area of Trial Psoriasis Approved Indication investigational Clinical Trial Results Database Page 3 Study

More information

TERME 3000, MORAVSKE TOPLICE, SLOVENIA

TERME 3000, MORAVSKE TOPLICE, SLOVENIA , MEDICAL TREATMENTS WHY MEDICAL IN TERME 3000, MORAVSKE TOPLICE NATURAL BENEFICAL FACTOR BLACK SODIUM CHLORIDE HYDROGENE-CARBONATE WATER & MUD MATURED IN BLACK THERMAL WATER The black sodium chloride

More information

F r e q u e n t l y A s k e d Q u e s t i o n s

F r e q u e n t l y A s k e d Q u e s t i o n s Acne who specializes in treating skin problems) about how you can help prevent acne and if treatment would help you. Q: What is acne? A: Acne is a disorder that causes outbreaks of skin lesions commonly

More information

NP/PA Clinical Hepatology Fellowship Summary of Year-Long Curriculum

NP/PA Clinical Hepatology Fellowship Summary of Year-Long Curriculum OVERVIEW OF THE FELLOWSHIP The goal of the AASLD NP/PA Fellowship is to provide a 1-year postgraduate hepatology training program for nurse practitioners and physician assistants in a clinical outpatient

More information

Adalimumab for the treatment of psoriasis

Adalimumab for the treatment of psoriasis DOI: 10.3310/hta13suppl2/07 Health Technology Assessment 2009; Vol. 13: Suppl. 2 Adalimumab for the treatment of psoriasis D Turner, J Picot,* K Cooper and E Loveman Southampton Health Technology Assessments

More information

Leukocytoclastic Vasculitis and Stasis Dermatitis With Id Reaction

Leukocytoclastic Vasculitis and Stasis Dermatitis With Id Reaction Id Reaction December 01, 2007 By David L. Kaplan, MD [1] A Photo Quiz to Hone Dermatologic Skills Case 1: A slightly pruritic eruption developed on the lower legs of a 39-year-old woman after she had an

More information

Jerry Bagel, MD of Windsor Dermatology Home of the Psoriasis Treatment Center of Central New Jersey

Jerry Bagel, MD of Windsor Dermatology Home of the Psoriasis Treatment Center of Central New Jersey JULY 2012 Jerry Bagel, MD of Windsor Dermatology Home of the Psoriasis Treatment Center of Central New Jersey Restoring Quality of Life for Psoriatic Patients Throughout NJ and Beyond Jerry Bagel, MD of

More information

SQUAMOUS CELL CARCINOMA

SQUAMOUS CELL CARCINOMA SQUAMOUS CELL CARCINOMA What are the aims of this leaflet? This leaflet has been written to help you understand more about squamous cell carcinomas of the skin. It tells you what they are, what causes

More information

D.RIGOPOULOS, D.IOANNIDES,* D.KALOGEROMITROS, S.GREGORIOU AND A.KATSAMBAS

D.RIGOPOULOS, D.IOANNIDES,* D.KALOGEROMITROS, S.GREGORIOU AND A.KATSAMBAS British Journal of Dermatology 24; 151: 171 175. DOI: 1.1111/j.1365-2133.24.628.x Therapeutics Pimecrolimus cream 1% vs. betamethasone 17-valerate Æ1% cream in the treatment of seborrhoeic dermatitis.

More information